EphA2 as Target of Anticancer Immunotherapy: Identification of HLA-A*0201-Restricted Epitopes

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8476-8480

  Alves, Pedro M S ^a   Faure, Olivier ^a,c   Graff Dubois, Stéphanie ^a   Gross, David Alexandre ^a   Cornet, Sébastien ^a   Chouaib, Salem ^a   Miconnet, Isabelle ^a   Lemonnier, François A ^b   Kosmatopoulos, Kostas ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT PASTEUR   (France)

^c Immuno Designed Molecules   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN A2; EPITOPE; HLA A ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL STRAIN COS7; COLON CANCER; CYTOTOXIC T LYMPHOCYTE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN PROCESSING; PROTEIN STABILITY; SARCOMA; STOMACH CANCER; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR REJECTION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; NEOPLASMS; PEPTIDE FRAGMENTS; RECEPTOR, EPHA2; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0347625928     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
2. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
3. Salgaller, M. L., Lodge, P. A., McLean, J. G., Tjoa, B. A., Loftus, D. J., Ragde, H., Kenny, G. M., Rogers, M., Boynton, A. L., and Murphy, G. P. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate, 35: 144-151, 1998.
4. Kugler, A., Stuhler, G., Walden, P., Zoller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Muller, C. A., Becker, V., Gross, A. J., Hemmerlein, B., Kanz, L., Muller, G. A., and Ringert, R. H. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med., 6: 332-336, 2000.
5. Boon, T., and Old, L. Cancer tumor antigens. Curr. Opin. Immunol., 1997: 681-683, 1997.
6. Vonderheide, R., Hahn, W., Schultze, J., and Nadler, L. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity, 10: 673-679, 1999.
7. Andersen, M., Pedersen, L., Becker, J., and Straten, P. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res., 61: 869-872, 2000.
8. Schmitz, M., Diestelkoetter, P., Weigle, B., Schmachtenberg, F., Stevanovic, S., Ockert, D., Rammensee, H-G., and Rieber, E. P. Generation of Survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res., 60: 4845-4849, 2000.
9. Holder, N., and Klein, R. Eph receptors and ephrins: effectors of morphogenesis. Development (Camb.), 126: 2033-2044, 1999.
10. Dodelet, V. C., and Pasquale, E. B. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene, 19: 5614-5619, 2000.
11. Easty, D. J., Herlyn, M., and Bennett, D. C. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int. J. Cancer. 60: 129-136, 1995.
12. Nemoto, T., Ohashi, K., Akashi, T., Johnson, J., and Hirokawa, K. Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology, 65: 195-203, 1997.
13. Rosenberg, I. M., Goke, M., Kanai, M., Reinecker, H. C., and Podolsky, D. K. Epithelial cell kinase-B61: an autocrine loop modulating intestinal epithelial migration and barrier function. Am. J. Physiol., 273: G824-G832, 1997.
14. Zelinski, D., Zantek, N., Stewart, J., Irizarry, A., and Kinch, M. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res., 61: 2301-2306, 2001.
15. Walker-Daniels, J., Coffman, K., Azimi, M., Rhim, J. S., Bostwick, D. G., Snyder, P. Kerns, B. J., Waters, D. J., and Kinch, M. S. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate, 41: 275-280, 1999.
16. Kinch, M. S., Moore, M. B., and Harpole, D. H., Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res., 9: 613-618, 2003.
17. Miyazaki, T., Kato, H., Fukuchi, M., Nakajima, M., and Kuwano, H. EphA2 over expression correlates with poor prognosis in esophageal squamous cell carcinoma Int. J. Cancer, 103: 657-663, 2003.
18. Miao, H., Burnett, E., Kinch, M., Simon, E., and Wang, B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat. Cell Biol., 2: 62-69, 2000.
19. Dohn, M., Jiang, J., and Chen, X. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene. 20: 6503-6515, 2001.
20. Ogawa, K., Pasqualini, R., Lindberg, R., Kain, R., Freeman, A., and Pasquale, E. The ephrin-A1 ligand and its receptor, EphA2 are expressed during tumor neovascularization. Oncogene, 19: 6043-6052, 2000.
21. Hess, A. R., Seftor, E. A., Gardner, L. M., Carles-Kinch, K., Schneider, G. B., Seftor, R. E., Kinch, M. S., and Hendrix, M. J. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/ EphA2). Cancer Res., 61: 3250-3255, 2001.
22. Cheng, N., Brantley, D. M., Liu, H., Lin, Q., Enriquez, M., Gale, N., Yancopoulos, G., Cerretti, D. P., Daniel, T. O., and Chen, J. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol. Cancer Res., 1: 2-11, 2002.
23. b β2m double knockout mice. J. Exp. Med., 185: 2043-2051, 1997.
24. Tourdol, S., Scardino, A., Saloustrou, E., Gross, D., Pascolo, S., Cordopatis, P. Lemonnier, F., and Kosmatopoulos, K. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur. J. Immunol., 30: 3411-3421, 2000.
25. Parham, P., and Brodsky, F. M. Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum. Immunol., 3: 277-299, 1981.
26. Espevik, T., and Nissen-Meyer, J. A highly sensitive cell line, WEHI 164 clone 13 for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods, 95: 99-105, 1986.
27. Parker, K. C., Bednarek, M. A., and Coligan, J. E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side chains. J. Immunol., 152: 163-175, 1994.
28. Renkvist, N., Castelli, C., Robbins, P., and Parmiani, G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother., 50: 3-15, 2001.
29. Lindberg, R., and Hunter, T. cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell. Biol., 10: 6316-6324, 1990.
30. Munoz, J. J., Alonso, L. M., Sacedon, R., Crompton, T., Vicente, A., Jimenez, E. Varas, A., and Zapata, A. G. Expression and function of the Eph A receptors and their ligands ephrins A in the rat thymus. J. Immunol., 169: 177-184, 2002.
31. Jager, E., Jager, D., and Knuth, A. Clinical cancer vaccine trials. Curr. Opin. Immunol., 14: 178-182, 2002.